ReviewSkin appendage disorders2018
Antibiofilm Treatment for Onychomycosis and Chronic Fungal Infections.
Review in Skin appendage disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Antibiofilm efficacy of 1,064-nm neodymium-doped yttrium aluminum garnet laser onMicrobiology spectrum · 2026Article
- Combinatorial effect of fluconazole, itraconazole, and terbinafine with different culture extracts of Candida parapsilosis and Trichophyton spp. against Trichophyton rubrum.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Antibiofilm Effect ofPharmaceutics · 2023Article
- Dermatophytic Biofilms: Characteristics, Significance and Treatment Approaches.Journal of fungi (Basel, Switzerland) · 2023Review
- Rapid-killing efficacy substantiates the antiseptic property of the synergistic combination of carvacrol and nerol against nosocomial pathogens.Archives of microbiology · 2022Article
- Dermatophytomas: Clinical Overview and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- Photodynamic Therapy for the Treatment of Fungal Infections.Infection and drug resistance · 2022Review
- Onychomycosis: An Updated Review.Recent patents on inflammation & allergy drug discovery · 2020Review
- Innovative Physical Approaches for Onychomycosis: Peeling, Lasers and Beyond.Skin appendage disorders · 2019Article
- Chemical Peeling as an Innovative Treatment Alternative to Oral Antifungals for Onychomycosis in Special Circumstances.Skin appendage disorders · 2019Article
- Surgical avulsion of the nail plate as therapy for resistant onychomycosis: case series and literature review.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomycosis is a difficult-to-treat chronic fungal infection of the nail. The chronic nature of onychomycosis, with relevance to current treatment practices, could be attributed to host anergy, development of increased virulence in causal agents (multidrug resistance efflux pump), and biofilms. Biofilms must be disrupted prior to antifungal treatment suggesting the necessity of combination treatment. Once the biofilm has been disrupted, further techniques in addition to antifungal usage are suggested to ensure a positive prognosis including use of antimicrobial photodynamic therapy or low-frequency surface acoustic waves. Overall, with continued success in developing antibiofilm treatment for bacterial and yeast pathogens, therapy can be more quickly expanded to dermatophytes. With a rise in predisposing factors, it is important to preemptively address treatment for this disease with continued investigation into antibiofilm therapy including optimal treatment combinations and dosages targeted specifically at dermatophytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.